

Drug resistance interpretation: PR		HIVDB 9.5.1 (2023-11-05)
PI Major Mutations:	None	
PI Accessory Mutations:	None	
PR Other Mutations:	I13IV <small>91.82%, 1.22%</small> • K20R <small>100%, 2.78%</small> • E35D <small>100%, 6.52%</small> • M36I <small>100%, 6.52%</small> • R41K <small>100%, 4.58%</small> • R57K <small>100%, 4.58%</small> • L63LP <small>100%, 1.12%</small> • H69K <small>100%, 3.71%</small> • K70KR <small>100%, 1.22%</small> • L89M <small>100%, 3.64%</small>	
Protease Inhibitors		
atazanavir/r (ATV/r)	Susceptible	
darunavir/r (DRV/r)	Susceptible	
fosamprenavir/r (FPV/r)	Susceptible	
indinavir/r (IDV/r)	Susceptible	
lopinavir/r (LPV/r)	Susceptible	
nelfinavir (NFV)	Susceptible	
saquinavir/r (SQV/r)	Susceptible	
tipranavir/r (TPV/r)	Susceptible	
PR comments		
Other		
<ul style="list-style-type: none">K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.		

Mutation scoring: PR	HIVDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for PI.	

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations:

None

NNRTI Mutations:

None

RT Other Mutations:

K20R 100%
HIV-2_206 • V35T 100%
HIV-2_178 • T39G 100%
HIV-2_204 • K122E 100%
HIV-2_203 • D123N 100%
HIV-1_220 • S162A 100%
HIV-1_701 • K173L 100%
HIV-1_808 • Q174K 100%
HIV-1_808 • D177E 100%
HIV-1_788 • V179I 100%
HIV-1_812 • T200K 100%
HIV-1_11 • I202V 100%
HIV-1_75 • Q207A 100%
HIV-1_520 • R211S 100%
HIV-1_553 • K223KR 100%
HIV-1_553 • K358R 100%
HIV-1_85

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)

Susceptible

zidovudine (AZT)

Susceptible

stavudine (D4T)

Susceptible

didanosine (DDI)

Susceptible

emtricitabine (FTC)

Susceptible

lamivudine (3TC)

Susceptible

tenofovir (TDF)

Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

Susceptible

efavirenz (EFV)

Susceptible

etravirine (ETR)

Susceptible

nevirapine (NVP)

Susceptible

rilpivirine (RPV)

Susceptible

RT comments

Other

V179I

is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

Mutation scoring: RT	HIVDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for NRTI.	
No drug resistance mutations were found for NNRTI.	

Drug resistance interpretation: IN		HIVDB 9.5.1 (2023-11-05)
INSTI Major Mutations:	None	
INSTI Accessory Mutations:	None	
IN Other Mutations:	E11ED <small>100% HIV-2_71</small> • V31I <small>100% HIV-1_553</small> • K34KR <small>100% HIV-1_553</small> • I60M <small>100% HIV-2_77</small> • I72V <small>100% HIV-1_181</small> • T112V <small>100% HIV-1_49</small> • I113V <small>100% HIV-1_49</small> • T124A <small>100% HIV-1_125</small> • T125A <small>100% HIV-1_125</small> • V126F <small>100% HIV-1_125</small> • G134N <small>100% HIV-1_125</small> • I135V <small>100% HIV-1_125</small> • K136S <small>100% HIV-1_125</small> • D167E <small>100% HIV-1_178</small> • V201I <small>100% HIV-1_207</small> • Y227F <small>100% HIV-1_553</small> • L234I <small>100% HIV-1_281</small> • N254K <small>100% HIV-1_114</small> • S255G <small>100% HIV-1_114</small> • S283G <small>100% HIV-1_553</small>	
Integrase Strand Transfer Inhibitors		
bictegravir (BIC)	Susceptible	
cabotegravir (CAB)	Susceptible	
dolutegravir (DTG)	Susceptible	
elvitegravir (EVG)	Susceptible	
raltegravir (RAL)	Susceptible	
Mutation scoring: IN		HIVDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for INSTI.		